Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
Medtronic PLC (MDT)
The company has Return on Asset of 0.0423 % which means that on every $100 spent on assets, it made $0.0423 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0817 %, implying that it generated $0.0817 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2024, whereas Return On Capital Employed is likely to drop 0.05 in 2024. Total Current Liabilities is likely to gain to about 10.9 B in 2024. Liabilities And Stockholders Equity is likely to gain to about 109.8 B in 2024The entity currently falls under 'Mega-Cap' category with a total capitalization of 106.98 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Medtronic PLC's market, we take the total number of its shares issued and multiply it by Medtronic PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Medtronic PLC secures a last-minute Real Value of $86.16 per share. The latest price of the firm is $81.29. Our model forecasts the value of Medtronic PLC from analyzing the firm fundamentals such as Return On Equity of 0.0817, profit margin of 0.13 %, and Current Valuation of 124.05 B as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend acquiring undervalued stocks and selling overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Viatris (MYL)
The company has Return on Asset of 3.63 % which means that on every $100 spent on assets, it made $3.63 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 2.22 %, implying that it generated $2.22 on every 100 dollars invested. Viatris' management efficiency ratios could be used to measure how well Viatris manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Mid-Cap' category with a total capitalization of 8.59 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Viatris's market, we take the total number of its shares issued and multiply it by Viatris's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Universal Health Services (UHS)
The company has Return on Asset of 0.0535 % which means that on every $100 spent on assets, it made $0.0535 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1182 %, implying that it generated $0.1182 on every 100 dollars invested. Universal Health's management efficiency ratios could be used to measure how well Universal Health manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.1 in 2024, whereas Return On Tangible Assets are likely to drop 0.06 in 2024. At this time, Universal Health's Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 12.1 B in 2024, whereas Intangible Assets are likely to drop slightly above 85.3 M in 2024. The company currently falls under 'Large-Cap' category with a total capitalization of 10.85 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Universal Health's market, we take the total number of its shares issued and multiply it by Universal Health's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the company appears to be fairly valued. Universal Health Services has a current Real Value of $160.12 per share. The regular price of the company is $164.91. Our model measures the value of Universal Health Services from inspecting the company fundamentals such as Return On Equity of 0.12, shares outstanding of 60.08 M, and Operating Margin of 0.09 % as well as reviewing its technical indicators and probability of bankruptcy. In general, most investors recommend acquiring undervalued stocks and selling overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
ResMed Inc (RMD)
The company has Return on Asset of 0.1119 % which means that on every $100 spent on assets, it made $0.1119 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2166 %, implying that it generated $0.2166 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. As of April 23, 2024, Return On Tangible Assets is expected to decline to 0.13. In addition to that, Return On Capital Employed is expected to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 477.5 M, whereas Deferred Long Term Asset Charges is forecasted to decline to about 42.6 M. This firm currently falls under 'Large-Cap' category with a total capitalization of 26.53 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ResMed's market, we take the total number of its shares issued and multiply it by ResMed's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
1.91 Billion
At present, ResMed's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
Stryker (SYK)
The company has Return on Asset of 0.0687 % which means that on every $100 spent on assets, it made $0.0687 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1798 %, implying that it generated $0.1798 on every 100 dollars invested. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Stryker's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.11 this year, although the value of Return On Tangible Assets will most likely fall to 0.10. At this time, Stryker's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 41.9 B this year, although the value of Non Current Liabilities Other will most likely fall to about 1.8 B. This firm currently falls under 'Mega-Cap' category with a total capitalization of 124.67 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Stryker's market, we take the total number of its shares issued and multiply it by Stryker's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the company appears to be fairly valued. Stryker has a current Real Value of $324.1 per share. The regular price of the company is $334.91. Our model measures the value of Stryker from inspecting the company fundamentals such as Shares Outstanding of 380.47 M, return on equity of 0.18, and Operating Margin of 0.24 % as well as reviewing its technical indicators and probability of bankruptcy. In general, most investors recommend picking up undervalued stocks and discarding overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
Edwards Lifesciences Corp (EW)
The company has Return on Asset (ROA) of 0.1225 % which means that for every $100 of assets, it generated a profit of $0.1225. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.2234 %, which means that it produced $0.2234 on every 100 dollars invested by current stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.1 in 2024. Return On Capital Employed is likely to drop to 0.14 in 2024. At this time, Edwards Lifesciences' Intangibles To Total Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to climb to 4.91 in 2024, whereas Debt To Assets are likely to drop 0.07 in 2024. The firm currently falls under 'Large-Cap' category with a market capitalization of 52.34 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Edwards Lifesciences's market, we take the total number of its shares issued and multiply it by Edwards Lifesciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Macroaxis Gross Profit
Macroaxis Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Macroaxis previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Macroaxis Gross Profit growth over the last 10 years. Please check Macroaxis' gross profit and other fundamental indicators for more details.
Story appears to be empty
Medtronic PLC (MDT)
The company has Return on Asset of 0.0423 % which means that on every $100 spent on assets, it made $0.0423 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0817 %, implying that it generated $0.0817 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2024, whereas Return On Capital Employed is likely to drop 0.05 in 2024. Total Current Liabilities is likely to gain to about 10.9 B in 2024. Liabilities And Stockholders Equity is likely to gain to about 109.8 B in 2024The entity currently falls under 'Mega-Cap' category with a total capitalization of 106.98 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Medtronic PLC's market, we take the total number of its shares issued and multiply it by Medtronic PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Medtronic PLC secures a last-minute Real Value of $86.16 per share. The latest price of the firm is $81.29. Our model forecasts the value of Medtronic PLC from analyzing the firm fundamentals such as Return On Equity of 0.0817, profit margin of 0.13 %, and Current Valuation of 124.05 B as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend acquiring undervalued stocks and selling overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Viatris (MYL)
The company has Return on Asset of 3.63 % which means that on every $100 spent on assets, it made $3.63 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 2.22 %, implying that it generated $2.22 on every 100 dollars invested. Viatris' management efficiency ratios could be used to measure how well Viatris manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Mid-Cap' category with a total capitalization of 8.59 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Viatris's market, we take the total number of its shares issued and multiply it by Viatris's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Universal Health Services (UHS)
The company has Return on Asset of 0.0535 % which means that on every $100 spent on assets, it made $0.0535 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1182 %, implying that it generated $0.1182 on every 100 dollars invested. Universal Health's management efficiency ratios could be used to measure how well Universal Health manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.1 in 2024, whereas Return On Tangible Assets are likely to drop 0.06 in 2024. At this time, Universal Health's Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 12.1 B in 2024, whereas Intangible Assets are likely to drop slightly above 85.3 M in 2024. The company currently falls under 'Large-Cap' category with a total capitalization of 10.85 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Universal Health's market, we take the total number of its shares issued and multiply it by Universal Health's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the company appears to be fairly valued. Universal Health Services has a current Real Value of $160.12 per share. The regular price of the company is $164.91. Our model measures the value of Universal Health Services from inspecting the company fundamentals such as Return On Equity of 0.12, shares outstanding of 60.08 M, and Operating Margin of 0.09 % as well as reviewing its technical indicators and probability of bankruptcy. In general, most investors recommend acquiring undervalued stocks and selling overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
ResMed Inc (RMD)
The company has Return on Asset of 0.1119 % which means that on every $100 spent on assets, it made $0.1119 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2166 %, implying that it generated $0.2166 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. As of April 23, 2024, Return On Tangible Assets is expected to decline to 0.13. In addition to that, Return On Capital Employed is expected to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 477.5 M, whereas Deferred Long Term Asset Charges is forecasted to decline to about 42.6 M. This firm currently falls under 'Large-Cap' category with a total capitalization of 26.53 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ResMed's market, we take the total number of its shares issued and multiply it by ResMed's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Short Long Term Debt Total
1.91 Billion
At present, ResMed's Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.
Stryker (SYK)
The company has Return on Asset of 0.0687 % which means that on every $100 spent on assets, it made $0.0687 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1798 %, implying that it generated $0.1798 on every 100 dollars invested. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Stryker's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.11 this year, although the value of Return On Tangible Assets will most likely fall to 0.10. At this time, Stryker's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 41.9 B this year, although the value of Non Current Liabilities Other will most likely fall to about 1.8 B. This firm currently falls under 'Mega-Cap' category with a total capitalization of 124.67 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Stryker's market, we take the total number of its shares issued and multiply it by Stryker's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the company appears to be fairly valued. Stryker has a current Real Value of $324.1 per share. The regular price of the company is $334.91. Our model measures the value of Stryker from inspecting the company fundamentals such as Shares Outstanding of 380.47 M, return on equity of 0.18, and Operating Margin of 0.24 % as well as reviewing its technical indicators and probability of bankruptcy. In general, most investors recommend picking up undervalued stocks and discarding overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
Edwards Lifesciences Corp (EW)
The company has Return on Asset (ROA) of 0.1225 % which means that for every $100 of assets, it generated a profit of $0.1225. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.2234 %, which means that it produced $0.2234 on every 100 dollars invested by current stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.1 in 2024. Return On Capital Employed is likely to drop to 0.14 in 2024. At this time, Edwards Lifesciences' Intangibles To Total Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to climb to 4.91 in 2024, whereas Debt To Assets are likely to drop 0.07 in 2024. The firm currently falls under 'Large-Cap' category with a market capitalization of 52.34 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Edwards Lifesciences's market, we take the total number of its shares issued and multiply it by Edwards Lifesciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Money Flow Index Now
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
